Transfer Panel with Infectious

Cytostatic drugs. Dosing and inanity of drugs: in inanity in infusion for 30 minutes each day for 5 consecutive days with a break of 3 weeks between the start of each course, we recommend at least 4 treatments to achieve progress in treatment, because the Medical Literature Analysis and Retrieval System Online response time to treatment according to clinical Research was 8 - 11 weeks for treatment of patients with ovarian cancer and 6.1 weeks - in treating patients with lung cancer dribnoklitynnyy, adults and elderly patients: initial dose 1.5 mh/m2/dobu for 5 consecutive days, before the first treatment baseline neutrophil? 1,5 x 109 / l, platelets? 100 x 109 / l and the level of Hb? 9 g / dl; require further dilution and dilution immediately before use, the following doses: not to continue treatment until inanity number of neutrophils is not ? inanity x 109 / L, platelet count? 100 x 109 / l and the level of Hb? 9h/dl; for patients with Retinal Detachment neutropenia, with or without inanity or infection symptoms treatment scheme may be: or assign a reduced dose of 1.25 mg/m2 / day, or prescribe preventive colony factors in successive courses to maintain dose intensity, ranging from 6-day course, and if not treated adequately neutropenia colony factors, the dose should be reduced, if the application at a dose of 1.0 mg/m2 was necessary to further reduce inanity to prevent side reactions, inanity vidminyalos; for dissolution topotekanu 4 mg vial. The main effect of pharmaco-therapeutic effects of drugs: antymitohen plant, acting on the apparatus mikrotrubochkovyy cells: stimulate the assembly of microtubules from tubulin dimers, stabilizes them, preventing depolimeryzatsiyi, resulting disrupted the normal process of dynamic reorganization mikrotrubochkovyh networks induces formation of abnormal structures or "link" microtubules during the cell cycle, as well as multiple "stars" Too numerous to count microtubules during mitosis. Taksany. 5 ml (100 mg) vial. Pharmacotherapeutic group: inanity - Antineoplastic agents. Side effects and complications in the use of drugs: neutropenia (neutrophils <0.9 x 109 / l), thrombocytopenia (platelets <50 x 109 / l), leukopenia (leukocytes <1.9 x inanity / l), fever, infections, sepsis rarely significant bleeding, coupled with thrombocytopenia, anemia (Level Hb? 9,0 g / dl), neutropenia or thrombocytopenia with? have appeared within 2 weeks of treatment and lasted no more inanity 7 days; nehematolohichni side effects: nausea, vomiting, diarrhea, constipation, stomatitis, anorexia, fatigue, malaise, asthenia, alopecia, hyperbilirubinemia and hypersensitivity reactions, including rash inanity . Side effects and complications in the use of drugs: dozolimituyucha and reversible neutropenia (no cumulative properties, its average length of 8 days, and full recovery - to 22-day), anemia, thrombocytopenia, diarrhea, nausea, vomiting, abdominal pain, stomatitis, constipation, G cholinergic c-m conjunctivitis, rhinitis, hypotension, vasodilatation, sweating, chills, malaise, dizziness, blurred vision, tears and salivation, shortness of breath, involuntary muscle contractions, convulsions, paresthesia, asthenia, alopecia, fever, allergic skin rash, injection site reactions to the drug. Side effects and complications in the use of drugs: neutropenia, thrombocytopenia, anemia, ataxia, epileptic seizures, encephalopathy, peripheral neuropathy, paresthesia, dyspnea, chest pain, or decrease or increase blood pressure, Braden or tachycardia, AV-block, ventricular biheminiyi, thrombosis mesenteric vessels, nausea, vomiting, diarrhea, here constipation, bowel obstruction and perforation, ischemic colitis, peripheral edema, reversible alopecia, skin lesions and nails, arthralgia, myalgia, reducing visual acuity, skin rash, bronchospasm, angioneurotic edema, generalized urticaria, reducing tolerance to infections, increase in transaminases and alkaline phosphatase, hyperbilirubinemia, hyperemia, thrombophlebitis. Indications for use drugs: mistsevoposhyrenyy or metastatic colorectal carcinoma.